Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer

BMC Cancer

Table 3 Diagnostic accuracy of biomarkers in predicting PCa based on optimal cutoff values from ROC analysis*

Biomarker	AUC	95% CI	Pvalue
β2M ≥ 40 DU	0.668	0.628 – 0.748	<0.001*
PGA3 ≥ 190 DU	0.625	0.547 – 0.710	0.008*
MUC3 ≥ 185 DU	0.618	0.532 – 0.700	0.009*
PSA categories, ng/mL (0–4.0, 4.1-10, >10)	0.734	0.653 – 0.814	0.007*
β2M + PGA3 + MUC3	0.710	0.631 – 0.788	<0.001*
β2M + PGA3 + MUC3 + PSA categories	0.812	0.740 – 0.885	<0.001*

AUC = area under the curve; CI = confidence interval, DU = densitometric unit. * Determined by the Youden index.

ISSN: 1471-2407